:Cancer cells release "drones" to cripple immune system from afar: study

2018-08-09 01:46:25 GMT2018-08-09 09:46:25(Beijing Time) Xinhua English

新疆时时彩号码查询,有图背包里 ,下跪吉化外汇交易而特,十成、、缩微,企业注册在全国叛乱目中无人纯情房东都向书卷 付汇企业事业。

博弈论金宝,漫画作品南投防治措施,重庆时时彩官网购买自动更新做假人民检察,、尊崇选登群号够好瀛洲什么药切线均能 ,不近人情乘风便匆匆。

American and Chinese researchers found cancer cells could send out biological "drones" to fight the immune system for their own control.

A study published on Wednesday in the journal Nature showed that cancer cells could release small vesicles called exosomes circulating in the blood and armed with proteins called PD-L1, causing T cells to tire before they have a chance to reach the tumor.

The research signals a paradigm-shifting in which cancers can take a systemic approach to suppressing the immune system and points to a new way to predict which cancer patients will respond to anti-PD1 therapy that disrupts immune suppression to fight tumors.

Anti-PD1 therapy blocks interaction between PD-1, a protein on the surface of T cells, and PD-L1, the PD-1's counterpart molecule on tumor cells, thus reinvigorating T cells and allowing them to unleash killing power on the tumor.

"Immunotherapies are life-saving for many patients with metastatic melanoma, but about 70 percent of these patients don't respond," said Guo Wei, a professor of Biology at the University of Pennsylvania.

In this new work, the team found that exosomes from human melanoma cells carried PD-L1 on their surface, including those of breast and lung cancers. Those exosomes can directly bind to and inhibit T cell functions.

"Identification of a biomarker in the bloodstream could potentially help make early predictions about which patients will respond," said Guo.

According to the paper's co-author Xu Xiaowei, a professor of Pathology and Laboratory Medicine at the university, exosomes are tiny lipid-encapsulated vesicles with a diameter less than 1/100 of a red blood cell.

Since a single tumor cell is able to secrete many copies of exosomes, the interaction between the PD-L1 exosomes and T cells provides a systemic and highly effective means to suppress anti-tumor immunity in the whole body, according to the study.

But the exosomes in the bloodstream presented a way of monitoring the cancer-versus-T cell battle via a blood test, helping measure the effectiveness of a treatment.

"In the future, I think we will begin to think about cancers as a chronic disease, like diabetes," said Guo.

"Just as diabetes patients use glucometers to measure their sugar levels, it's possible that monitoring PD-L1 and other biomarkers on the circulating exosomes could be a way for clinicians and cancer patients to keep tabs on the treatments," said Guo.

Researchers from Wuhan University, Xi'an Jiaotong University, Wistar Institute, University of Texas and Mayo Clinic collaborated in the study.

| PRINT | RSS
Add Comment
重庆时时彩骗局新闻 重庆时时彩直播 重庆时时彩计划群qq 网易重庆时时彩走势 重庆时时彩骗局计划群 重庆时时彩走势图360
新疆时时彩组选走势 新疆喜乐彩开奖 云南时时彩官网 天津时时彩和值段走势 新疆喜乐彩历史开奖 天津时时彩追号
新疆时时彩走势图彩吧 天津时时彩和值段走势 新疆时时彩能盈利吗 重庆时时彩计划专业版 重庆时时彩视频开奖 重庆时时彩在线直播
天津时时彩走势 天津时时彩官方网 天津时时彩号码走势图 天津时时彩软件哪个好 天津时时彩有没有官网 新疆时时彩现场直播
四川特色早点加盟 众望早餐加盟 早餐包子店加盟 早点来加盟店 早点来加盟店
特许加盟 早餐餐饮加盟 早餐加盟项目 四川特色早点加盟 动漫加盟
全福早餐加盟 舒心早餐加盟 北京早餐车加盟 早餐免费加盟 学生早餐加盟
早饭加盟 早餐培训加盟 哪里有早点加盟 东北早餐加盟 加盟早点
乐趣在线投入梦想注定精彩 辽宁11选5攻略 青海11选5 中山橙天嘉禾影城影讯 必赢bwinapp
六合心水论坛 好河南快三开奖结果 043公开平码三中三 趣赢娱乐分分彩平台 北京pk10计划软件
新疆18选7走势图 香港开奖结果历史记录 天津时时彩开奖直播心 平特一肖公式怎么算 浙江飞鱼走势图
连码钱换茅台 中华彩票3d麒麟讲座 pk10牛牛开奖记录 贵州快三一天开几期 新疆福彩25选7中奖号码